TP63 antibodies target isoforms of the TP63 protein, which functions as a transcriptional activator or repressor depending on isoform composition . HRP conjugation amplifies signal detection in assays, making it indispensable for visualizing low-abundance targets.
TP63 regulates genes involved in epithelial morphogenesis, limb development, and tumor suppression. HRP-conjugated antibodies have been pivotal in studies demonstrating:
Ferroptosis Suppression: TP63 upregulates SLC7A5 in head and neck squamous cell carcinoma (HNSCC), inhibiting ferroptosis (iron-dependent cell death) and promoting therapy resistance .
Cancer Biomarker Potential: Overexpression correlates with poor prognosis in esophageal squamous cell carcinoma (ESCC) and HNSCC .
Isoform-Specific Roles: ΔN isoforms dominate in epithelial stem cells, while TA isoforms drive apoptosis in response to DNA damage .
Zebrafish Tissue: Detected TP63 at ~43–52 kDa using a 1:2,500 dilution .
Recombinant Protein: Validated specificity using E. coli-expressed TP63 (~91 kDa with tags) .
Esophageal Cancer: Strong nuclear staining in recurrent ESCC tissues, correlating with poor survival .
Prostate and Lung Cancer: Distinct TP63 expression in basal epithelial layers .
Therapeutic Targeting: TP63-mediated SLC7A5 upregulation in HNSCC highlights a pathway for overcoming immunotherapy resistance .
Diagnostic Utility: High TP63 expression in ESCC recurrence suggests its role as a prognostic biomarker .
Technical Limitations: Small sample sizes in single-cell studies and incomplete mechanistic validation require further investigation .
Blocking: 5% non-fat milk in PBST reduces background in WB .
Antigen Retrieval: EDTA buffer (pH 8.0) enhances IHC signal in paraffin-embedded tissues .
Controls: Anti-thio tags (for recombinant proteins) and isotype-matched antibodies ensure specificity .